US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
US9950282B2
(en)
|
2012-03-15 |
2018-04-24 |
Flodesign Sonics, Inc. |
Electronic configuration and control for acoustic standing wave generation
|
US9458450B2
(en)
|
2012-03-15 |
2016-10-04 |
Flodesign Sonics, Inc. |
Acoustophoretic separation technology using multi-dimensional standing waves
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
US10967298B2
(en)
|
2012-03-15 |
2021-04-06 |
Flodesign Sonics, Inc. |
Driver and control for variable impedence load
|
PL2855667T3
(pl)
*
|
2012-05-25 |
2024-03-25 |
Cellectis |
Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii
|
US20150017136A1
(en)
*
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
JP6401704B2
(ja)
*
|
2012-10-10 |
2018-10-10 |
サンガモ セラピューティクス, インコーポレイテッド |
T細胞を修飾する化合物およびその使用
|
PT3300745T
(pt)
|
2013-02-15 |
2019-11-27 |
Univ California |
Recetor de antigénio quimérico e métodos de utilização do mesmo
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
AU2014236726A1
(en)
*
|
2013-03-14 |
2015-09-17 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling T cell proliferation
|
JP6005572B2
(ja)
*
|
2013-03-28 |
2016-10-12 |
Kddi株式会社 |
動画像符号化装置、動画像復号装置、動画像符号化方法、動画像復号方法、およびプログラム
|
EP3789487A1
(en)
|
2013-04-03 |
2021-03-10 |
Memorial Sloan Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
US11311575B2
(en)
*
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
WO2014186469A2
(en)
|
2013-05-14 |
2014-11-20 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
CA2913830C
(en)
|
2013-05-29 |
2021-06-29 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
WO2015070083A1
(en)
|
2013-11-07 |
2015-05-14 |
Editas Medicine,Inc. |
CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
|
CN105765061A
(zh)
*
|
2013-11-22 |
2016-07-13 |
塞勒克提斯公司 |
工程化耐受化疗药物的t-细胞用于免疫治疗的方法
|
RU2689558C1
(ru)
*
|
2013-11-22 |
2019-05-28 |
Селлектис |
Способ конструирования аллогенных и устойчивых к лекарственным препаратам т-клеток для иммунотерапии
|
EP3071686B1
(en)
*
|
2013-11-22 |
2020-07-22 |
Cellectis SA |
Method for generating batches of allogeneic t-cells with averaged potency
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
US9840699B2
(en)
|
2013-12-12 |
2017-12-12 |
President And Fellows Of Harvard College |
Methods for nucleic acid editing
|
WO2015095811A2
(en)
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
EP3808410A1
(en)
*
|
2013-12-20 |
2021-04-21 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
WO2015105955A1
(en)
|
2014-01-08 |
2015-07-16 |
Flodesign Sonics, Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
WO2015107075A1
(en)
*
|
2014-01-14 |
2015-07-23 |
Cellectis |
Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
|
EP3690044B1
(en)
|
2014-02-11 |
2024-01-10 |
The Regents of the University of Colorado, a body corporate |
Crispr enabled multiplexed genome engineering
|
EP3105317B1
(en)
*
|
2014-02-14 |
2018-09-19 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
CA2937750A1
(en)
|
2014-02-14 |
2015-08-20 |
Bellicum Pharmaceuticals, Inc. |
Methods for activating t cells using an inducible chimeric polypeptide
|
DK3105335T3
(da)
|
2014-02-14 |
2020-01-13 |
Univ Texas |
Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
|
JP6665102B2
(ja)
*
|
2014-02-21 |
2020-03-13 |
セレクティスCellectis |
制御性t細胞をインサイチューで阻害するための方法
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
US20230027993A1
(en)
|
2014-03-05 |
2023-01-26 |
Autolus Limited |
Methods
|
KR102235202B1
(ko)
*
|
2014-03-05 |
2021-04-05 |
유씨엘 비즈니스 리미티드 |
T 세포 수용체 베타 불변 영역에 대한 항원 결합 도메인을 갖는 키메라 항원 수용체(car)
|
WO2015136001A1
(en)
*
|
2014-03-11 |
2015-09-17 |
Cellectis |
Method for generating t-cells compatible for allogenic transplantation
|
DK3119807T3
(da)
|
2014-03-19 |
2019-07-15 |
Cellectis |
Cd123-specifikke kimære antigenreceptorer til cancerimmunterapi
|
US9944702B2
(en)
|
2014-04-03 |
2018-04-17 |
Cellectis |
CD33 specific chimeric antigen receptors for cancer immunotherapy
|
JP2017513472A
(ja)
*
|
2014-04-11 |
2017-06-01 |
セレクティスCellectis |
アルギニンおよび/またはトリプトファン枯渇微小環境に対して抵抗性を有する免疫細胞を作製するための方法
|
EP3131927B8
(en)
*
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
EP3800248A3
(en)
*
|
2014-04-18 |
2021-08-04 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
AU2015254595B2
(en)
|
2014-05-02 |
2019-06-27 |
Cellectis |
CS1 specific multi-chain chimeric antigen receptor
|
US10738278B2
(en)
|
2014-07-15 |
2020-08-11 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
DK3453406T3
(da)
|
2014-07-29 |
2021-07-12 |
Cellectis |
ROR1(NTRKR1)-specifikke kimære antigenreceptorer til cancerimmunterapi
|
EP3177718B1
(en)
|
2014-07-30 |
2022-03-16 |
President and Fellows of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
EP3194432B1
(en)
|
2014-07-31 |
2019-04-10 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
JP6945444B2
(ja)
|
2014-08-08 |
2021-10-06 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
高親和性pd−1薬剤とその使用方法
|
WO2016036746A1
(en)
|
2014-09-02 |
2016-03-10 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
|
JP6810685B2
(ja)
*
|
2014-09-04 |
2021-01-06 |
セレクティスCellectis |
癌免疫療法のための栄養膜糖タンパク質(5t4、tpbg)特異的キメラ抗原受容体
|
CA2965224A1
(en)
*
|
2014-10-24 |
2016-04-28 |
Bcrt Holding Bv |
T cell-based immunotherapeutics
|
EP3215168B1
(en)
*
|
2014-10-31 |
2023-08-02 |
The Trustees of the University of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
GB201421096D0
(en)
*
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
EP3757211A1
(en)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
WO2016120217A1
(en)
|
2015-01-26 |
2016-08-04 |
Cellectis |
Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy
|
SG11201706041XA
(en)
|
2015-01-26 |
2017-08-30 |
Fate Therapeutics Inc |
Methods and compositions for inducing hematopoietic cell differentiation
|
US10557140B2
(en)
*
|
2015-02-02 |
2020-02-11 |
Industry-Academic Cooperation Foundation, Dankook University |
CTLA-4-targeting trans-splicing ribozyme for delivery of chimeric antigen receptor, and use thereof
|
AU2016214301B2
(en)
*
|
2015-02-06 |
2022-05-19 |
Cellectis |
Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
MX2017010721A
(es)
|
2015-02-24 |
2018-08-28 |
Univ California |
Interruptores transcripcionales activados mediante unión y métodos para su uso.
|
EP3089761B1
(en)
*
|
2015-03-02 |
2019-06-12 |
Innovative Cellular Therapeutics Co., Ltd. |
Reducing immune tolerance induced by pd l1
|
KR20170137079A
(ko)
|
2015-03-11 |
2017-12-12 |
셀렉티스 |
그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들
|
JP7362249B2
(ja)
*
|
2015-03-20 |
2023-10-17 |
チルドレンズ ナショナル メディカル センター |
ナイーブt細胞集団からのウイルスまたは他の抗原に特異的なt細胞の生成
|
GB201504840D0
(en)
*
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
WO2016166268A1
(en)
|
2015-04-17 |
2016-10-20 |
Cellectis |
Engineering animal or plant genome using dna-guided argonaute interference systems (dais) from mesophilic prokaryotes
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
US11021699B2
(en)
|
2015-04-29 |
2021-06-01 |
FioDesign Sonics, Inc. |
Separation using angled acoustic waves
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
WO2016179319A1
(en)
*
|
2015-05-04 |
2016-11-10 |
Cellerant Therapeutics, Inc. |
Chimeric antigen receptors with ctla4 signal transduction domains
|
HUE051661T2
(hu)
|
2015-05-18 |
2021-03-29 |
Tcr2 Therapeutics Inc |
Készítmények és gyógyászati felhasználások a TCR újraprogramozására fúziós fehérjék felhasználásával
|
AU2016263513A1
(en)
|
2015-05-20 |
2017-11-23 |
Cellectis |
Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
|
KR20180010229A
(ko)
|
2015-05-20 |
2018-01-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
공유 신생항원
|
MX2017015239A
(es)
|
2015-05-29 |
2018-02-19 |
Juno Therapeutics Inc |
Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
CA2986314C
(en)
|
2015-06-30 |
2024-04-23 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
CA2991301A1
(en)
*
|
2015-07-13 |
2017-01-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
US20170014449A1
(en)
*
|
2015-07-13 |
2017-01-19 |
Elwha LLC, a limited liability company of the State of Delaware |
Site-specific epigenetic editing
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
US11459540B2
(en)
|
2015-07-28 |
2022-10-04 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
US11474085B2
(en)
|
2015-07-28 |
2022-10-18 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
US10166255B2
(en)
|
2015-07-31 |
2019-01-01 |
Regents Of The University Of Minnesota |
Intracellular genomic transplant and methods of therapy
|
BR112018002600A2
(pt)
|
2015-08-11 |
2018-10-23 |
Cellectis |
células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38
|
EP4218777A3
(en)
*
|
2015-08-28 |
2023-08-23 |
The Trustees of the University of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
EP3340995A4
(en)
|
2015-08-28 |
2019-04-03 |
The Trustees Of The University Of Pennsylvania |
METHODS AND COMPOSITIONS FOR CELLS EXPRESSING A CHIMERIC INTRACELLULAR SIGNALING MOLECULE
|
AU2016333886B2
(en)
|
2015-10-05 |
2020-10-08 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
|
EP3756682B8
(en)
*
|
2015-10-05 |
2022-04-27 |
Precision Biosciences, Inc. |
Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017070429A1
(en)
*
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
EP3365356B1
(en)
|
2015-10-23 |
2023-06-28 |
President and Fellows of Harvard College |
Nucleobase editors and uses thereof
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
JP7092662B2
(ja)
*
|
2015-10-30 |
2022-06-28 |
チルドレンズ ナショナル メディカル センター |
ナイーブt細胞集団からのhpv抗原特異的t細胞の生成
|
ES2953925T3
(es)
|
2015-11-04 |
2023-11-17 |
Fate Therapeutics Inc |
Ingeniería genómica de células pluripotentes
|
JP2018533363A
(ja)
|
2015-11-04 |
2018-11-15 |
フェイト セラピューティクス,インコーポレイテッド |
造血細胞分化を誘導するための方法および組成物
|
CA3004421A1
(en)
*
|
2015-11-05 |
2017-05-11 |
Baylor College Of Medicine |
An efficient, scalable patient-derived xenograft system based on a chick chorioallantoic membrane (cam) in vivo model
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
US11352631B2
(en)
*
|
2015-12-18 |
2022-06-07 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
CN105505869A
(zh)
*
|
2015-12-21 |
2016-04-20 |
河南大学淮河医院 |
一种针对肿瘤干细胞的嵌合抗原受体t细胞
|
EP3184548A1
(en)
*
|
2015-12-23 |
2017-06-28 |
Miltenyi Biotec GmbH |
Chimeric antigen receptor with cytokine receptor activating or blocking domain
|
EP3399991A4
(en)
|
2016-01-08 |
2019-08-07 |
The Regents of The University of California |
REQUIRES ACTIVE HETERODIMER POLYPEPTIDES AND METHOD FOR USE THEREOF
|
EP3426690A4
(en)
*
|
2016-03-11 |
2019-10-09 |
Bluebird Bio, Inc. |
GENOMEDITIZED IMMUNEFFECTOR CELLS
|
GB201604213D0
(en)
*
|
2016-03-11 |
2016-04-27 |
Proximagen Ltd |
Drug combination and its use in therapy
|
US20190161530A1
(en)
*
|
2016-04-07 |
2019-05-30 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
BR112018070676A2
(pt)
*
|
2016-04-15 |
2019-02-05 |
Zymeworks Inc |
construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
|
EP3429633B1
(en)
|
2016-04-15 |
2021-02-24 |
Cellectis |
A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
US20190328783A1
(en)
|
2016-04-15 |
2019-10-31 |
Cellectis |
A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
|
KR102437015B1
(ko)
|
2016-04-15 |
2022-08-29 |
메모리얼 슬로안 케터링 캔서 센터 |
유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
US11085035B2
(en)
|
2016-05-03 |
2021-08-10 |
Flodesign Sonics, Inc. |
Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
|
WO2017223538A1
(en)
|
2016-06-24 |
2017-12-28 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods for generating barcoded combinatorial libraries
|
JP7195154B2
(ja)
*
|
2016-07-06 |
2022-12-23 |
セレクティス |
初代免疫細胞における逐次遺伝子編集
|
US11384156B2
(en)
|
2016-07-25 |
2022-07-12 |
The Nemours Foundation |
Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
|
JP7109789B2
(ja)
|
2016-08-02 |
2022-08-01 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を使用したtcrの再プログラム化のための組成物及び方法
|
GB2568182A
(en)
|
2016-08-03 |
2019-05-08 |
Harvard College |
Adenosine nucleobase editors and uses thereof
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
BR112019003327A2
(pt)
*
|
2016-08-24 |
2019-07-02 |
Sangamo Therapeutics Inc |
nucleases manipuladas de alvo específico
|
IL264639B2
(en)
|
2016-08-24 |
2024-01-01 |
Sangamo Therapeutics Inc |
Regulation of globulin gene expression using transgenic nucleases with zinc neurites
|
CN109843922B
(zh)
|
2016-09-02 |
2023-10-03 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
CA3035455A1
(en)
|
2016-09-08 |
2018-03-15 |
Bluebird Bio, Inc. |
Pd-1 homing endonuclease variants, compositions, and methods of use
|
US11096998B2
(en)
|
2016-09-14 |
2021-08-24 |
Janssen Biotech, Inc. |
Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereof
|
EP3519433A1
(en)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
WO2018067826A1
(en)
|
2016-10-05 |
2018-04-12 |
Cellular Dynamics International, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
ES2875959T3
(es)
|
2016-10-07 |
2021-11-11 |
Tcr2 Therapeutics Inc |
Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
|
CA3039812A1
(en)
|
2016-10-11 |
2018-04-19 |
Bluebird Bio, Inc. |
Tcr.alpha. homing endonuclease variants
|
KR102622411B1
(ko)
|
2016-10-14 |
2024-01-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
EP3529351A1
(en)
*
|
2016-10-19 |
2019-08-28 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
JP2020513248A
(ja)
|
2016-10-19 |
2020-05-14 |
フロデザイン ソニックス, インク.Flodesign Sonics, Inc. |
音響による親和性細胞抽出
|
WO2018073394A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Cell death inducing chimeric antigen receptors
|
DK3321280T3
(da)
|
2016-11-10 |
2021-02-22 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Immunmodulatorer til reduktion af immunresistens i et melanom og andre proliferative sygdomme
|
WO2018087285A1
(en)
|
2016-11-10 |
2018-05-17 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Or10h1 antigen binding proteins and uses thereof
|
WO2018098365A2
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
CN110494565A
(zh)
|
2016-12-02 |
2019-11-22 |
朱诺治疗学股份有限公司 |
工程化b细胞及相关组合物和方法
|
WO2018115189A1
(en)
|
2016-12-21 |
2018-06-28 |
Cellectis |
Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
|
CN110167591B
(zh)
|
2016-12-23 |
2023-09-26 |
宏观基因有限公司 |
Adam9结合分子及使用其的方法
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
CN110268050A
(zh)
*
|
2017-01-10 |
2019-09-20 |
综合医院公司 |
经修饰的t细胞和它们的使用方法
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
CN110612119A
(zh)
|
2017-02-07 |
2019-12-24 |
西雅图儿童医院(Dba西雅图儿童研究所) |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
EP3583203B1
(en)
*
|
2017-02-15 |
2023-11-01 |
2seventy bio, Inc. |
Donor repair templates multiplex genome editing
|
EP3589295A4
(en)
|
2017-02-28 |
2020-11-04 |
Endocyte, Inc. |
COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
CA3056542A1
(en)
|
2017-03-15 |
2018-09-20 |
Oxford Biomedica (Uk) Limited |
Method
|
RU2019133280A
(ru)
|
2017-03-22 |
2021-04-22 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
EP3601562A1
(en)
|
2017-03-23 |
2020-02-05 |
President and Fellows of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
US11690873B2
(en)
|
2017-03-31 |
2023-07-04 |
Cellectis Sa |
Universal chimeric antigen receptor T cells specific for CD22
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
|
CA3059643A1
(en)
|
2017-04-13 |
2018-10-18 |
Cellectis |
New sequence specific reagents targeting ccr5 in primary hematopoietic cells
|
KR20240059648A
(ko)
*
|
2017-04-19 |
2024-05-07 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
조작된 항원 수용체를 발현하는 면역 세포
|
DK3391907T3
(da)
|
2017-04-20 |
2020-03-09 |
Iomx Therapeutics Ag |
Intracellulær kinase sik3, der er associeret med resistens over for antitumorimmunresponser, og anvendelser deraf
|
MX2019013514A
(es)
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
MA49403A
(fr)
*
|
2017-06-12 |
2021-03-24 |
Obsidian Therapeutics Inc |
Compositions de pde5 et méthodes d'immunothérapie
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
EP3641785A1
(en)
|
2017-06-19 |
2020-04-29 |
Cellectis |
Anti-hbv combination therapies involving specific endonucleases
|
CN114350613A
(zh)
|
2017-06-20 |
2022-04-15 |
居里研究所 |
Suv39h1缺陷的免疫细胞
|
EP3641789A4
(en)
*
|
2017-06-22 |
2021-08-11 |
Board Of Regents, The University Of Texas System |
REGULATORY IMMUNE CELL PRODUCTION PROCESSES AND THEIR USES
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
EP3645036A1
(en)
*
|
2017-06-30 |
2020-05-06 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
US11053484B2
(en)
|
2017-06-30 |
2021-07-06 |
Precision Biosciences, Inc. |
Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
|
EP3640333A4
(en)
|
2017-07-14 |
2020-12-30 |
Cure Genetics Co., Ltd |
GENE EDITING SYSTEM AND GENE EDITING METHOD
|
CN111093696B
(zh)
|
2017-07-17 |
2023-10-27 |
詹森生物科技公司 |
抗iii型纤连蛋白结构域的抗原结合区及其使用方法
|
WO2019016360A1
(en)
|
2017-07-21 |
2019-01-24 |
Cellectis |
MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
|
US11903968B2
(en)
|
2017-07-21 |
2024-02-20 |
Cellectis |
Engineered immune cells resistant to tumor microenvironment
|
TW201908335A
(zh)
*
|
2017-07-25 |
2019-03-01 |
美國德州系統大學評議委員會 |
增強之嵌合抗原受體及其用途
|
WO2019020733A1
(en)
|
2017-07-26 |
2019-01-31 |
Cellectis |
METHODS OF IMMUNE CELL SELECTION OF THE ANTIGEN-DEPENDENT CHIMERIC ANTIGENIC RECEPTOR (CAR)
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
EP3676376A2
(en)
|
2017-08-30 |
2020-07-08 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
JP2020535128A
(ja)
|
2017-09-19 |
2020-12-03 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体t細胞治療のための組成物およびその使用
|
KR20200066616A
(ko)
|
2017-09-21 |
2020-06-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
|
SG11202002728VA
(en)
|
2017-10-03 |
2020-04-29 |
Juno Therapeutics Inc |
Hpv-specific binding molecules
|
WO2019072824A1
(en)
|
2017-10-09 |
2019-04-18 |
Cellectis |
IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
|
KR20200121782A
(ko)
|
2017-10-16 |
2020-10-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
MX2020004444A
(es)
|
2017-10-19 |
2020-07-22 |
Cellectis |
Integracion genica direccionada de genes de inhibidores de nk para terapia con celulas inmunes mejorada.
|
AU2018360566A1
(en)
|
2017-10-31 |
2020-05-21 |
Allogene Therapeutics, Inc. |
Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
KR20200100060A
(ko)
|
2017-11-17 |
2020-08-25 |
이오반스 바이오테라퓨틱스, 인크. |
미세 바늘 흡인물 및 소형 생검물로부터의 til 확장
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
WO2019106163A1
(en)
|
2017-12-01 |
2019-06-06 |
Cellectis |
Reprogramming of genetically engineered primary immune cells
|
CA3085784A1
(en)
|
2017-12-14 |
2019-06-20 |
Flodesign Sonics, Inc. |
Acoustic transducer driver and controller
|
US11793867B2
(en)
|
2017-12-18 |
2023-10-24 |
Biontech Us Inc. |
Neoantigens and uses thereof
|
EP3728563A4
(en)
|
2017-12-22 |
2021-11-10 |
Fate Therapeutics, Inc. |
ENHANCED IMMUNE EFFECTIVE CELLS AND THEIR USE
|
US20190194617A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Cell Design Labs, Inc. |
Single- and multi-chain chimeric antigen receptors
|
WO2019119822A1
(en)
*
|
2017-12-23 |
2019-06-27 |
Uwell Biopharma Inc. |
Pharmaceutical chimeric receptor composition and method thereof
|
WO2019129850A1
(en)
|
2017-12-29 |
2019-07-04 |
Cellectis |
Off-the-shelf engineered cells for therapy
|
EP3684399A1
(en)
|
2017-12-29 |
2020-07-29 |
Cellectis |
Method for improving production of car t cells
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
BR112020013848A2
(pt)
|
2018-01-08 |
2020-12-01 |
Iovance Biotherapeutics, Inc. |
métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
EP3508499A1
(en)
|
2018-01-08 |
2019-07-10 |
iOmx Therapeutics AG |
Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
|
AU2019209428A1
(en)
|
2018-01-22 |
2020-07-30 |
Endocyte, Inc. |
Methods of use for CAR T cells
|
AU2019216269A1
(en)
|
2018-01-30 |
2020-05-28 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
GB201801920D0
(en)
*
|
2018-02-06 |
2018-03-21 |
Autolus Ltd |
Polypeptides and methods
|
WO2019157454A1
(en)
*
|
2018-02-11 |
2019-08-15 |
Memorial Sloan-Kettering Cancer Center |
Non-hla restricted t cell receptors and uses thereof
|
AU2019231792A1
(en)
*
|
2018-03-09 |
2020-10-22 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
US20210017248A1
(en)
*
|
2018-03-16 |
2021-01-21 |
The Regents Of The University Of California |
Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
|
AU2019243315A1
(en)
|
2018-03-29 |
2020-09-24 |
Fate Therapeutics, Inc. |
Engineered immune effector cells and use thereof
|
EP3775238A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
PE20201345A1
(es)
|
2018-04-05 |
2020-11-25 |
Juno Therapeutics Inc |
Receptores de celulas t, y celulas disenadas que expresan los mismos
|
CA3095084A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
KR102617818B1
(ko)
|
2018-04-12 |
2023-12-27 |
프리시젼 바이오사이언시스 인코포레이티드 |
인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
MX2020011134A
(es)
|
2018-04-27 |
2020-11-11 |
Iovance Biotherapeutics Inc |
Proceso cerrado para expansion y edicion de genes de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia.
|
EP3790629A1
(en)
|
2018-05-11 |
2021-03-17 |
CRISPR Therapeutics AG |
Methods and compositions for treating cancer
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
WO2020007593A1
(en)
|
2018-07-02 |
2020-01-09 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
WO2020018825A1
(en)
|
2018-07-19 |
2020-01-23 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with bcma specificity and uses thereof
|
AU2019312411A1
(en)
*
|
2018-07-26 |
2021-01-07 |
Legend Biotech Ireland Limited |
Nef-containing T cells and methods of producing thereof
|
US20210177832A1
(en)
|
2018-08-20 |
2021-06-17 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
WO2020041384A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
|
BR112021004383A2
(pt)
|
2018-09-28 |
2021-08-03 |
Massachusetts Institute Of Technology |
proteína de fusão imunomoduladora, composição farmacêutica, ácido nucleico, vetor de expressão, célula transformada, método para a produção de uma proteína de fusão imunomoduladora, método para ativar, aumentar ou promover uma resposta por uma célula imune em um sujeito, método para inibir, reduzir ou suprimir uma resposta por uma célula imune em um sujeito, método para reduzir ou inibir o crescimento do tumor, método para tratar câncer em um sujeito, kit, uso de uma proteína de fusão imunomoduladora e método para reduzir ou inibir o crescimento do tumor ou tratar o câncer em um sujeito
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
US20220033775A1
(en)
|
2018-11-05 |
2022-02-03 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathways inhibitors
|
PE20211292A1
(es)
|
2018-11-05 |
2021-07-20 |
Iovance Biotherapeutics Inc |
Procesos para la produccion de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
|
JP2022512899A
(ja)
|
2018-11-05 |
2022-02-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
抗pd-1抗体に対して不応性のnsclc患者の治療
|
EP3877512A2
(en)
|
2018-11-05 |
2021-09-15 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
EP3887518A2
(en)
|
2018-11-28 |
2021-10-06 |
Board of Regents, The University of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
KR20210096648A
(ko)
|
2018-11-29 |
2021-08-05 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
자연 살해 세포의 생체외 확장을 위한 방법 및 이의 용도
|
US20200268797A1
(en)
|
2018-11-30 |
2020-08-27 |
Janssen Biotech, Inc. |
Gamma delta t cells and uses thereof
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
WO2020131547A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
KR20210136050A
(ko)
|
2019-03-01 |
2021-11-16 |
이오반스 바이오테라퓨틱스, 인크. |
액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
BR112021018606A2
(pt)
|
2019-03-19 |
2021-11-23 |
Harvard College |
Métodos e composições para editar sequências de nucleotídeos
|
CA3135799A1
(en)
|
2019-04-03 |
2020-10-08 |
Precision Biosciences, Inc. |
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
|
PE20212369A1
(es)
*
|
2019-04-26 |
2021-12-21 |
Allogene Therapeutics Inc |
Receptores de antigenos quimericos resistentes a rituximab y usos de estos
|
JP2022531185A
(ja)
|
2019-04-30 |
2022-07-06 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
遺伝子改変t細胞を標的化するcd19を使用するb細胞悪性病変の同種細胞療法
|
US11026973B2
(en)
|
2019-04-30 |
2021-06-08 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
EP3736330A1
(en)
|
2019-05-08 |
2020-11-11 |
European Molecular Biology Laboratory |
Modified adeno-associated virus (aav) particles for gene therapy
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
CA3142425A1
(en)
*
|
2019-06-01 |
2020-12-10 |
Sivec Biotechnologies, Llc |
A bacterial platform for delivery of gene-editing systems to eukaryotic cells
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
JP2022538688A
(ja)
|
2019-07-05 |
2022-09-05 |
イオックス セラピューティクス アーゲー |
IGSF11(VSIG3)のIgC2に結合する抗体及びその使用
|
CN114222815A
(zh)
|
2019-07-23 |
2022-03-22 |
记忆疗法公司 |
Suv39h1缺陷的免疫细胞
|
CN114174345A
(zh)
|
2019-07-24 |
2022-03-11 |
瑞泽恩制药公司 |
具有mage-a4特异性的嵌合抗原受体和其用途
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
JP2022544825A
(ja)
*
|
2019-08-20 |
2022-10-21 |
プレシジョン バイオサイエンシズ,インク. |
細胞免疫療法のためのリンパ球枯渇投与レジメン
|
US20220305056A1
(en)
|
2019-08-27 |
2022-09-29 |
Janssen Biotech, Inc. |
Chimeric antigen receptor system and uses thereof
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
BR112022003970A2
(pt)
|
2019-09-03 |
2022-06-21 |
Myeloid Therapeutics Inc |
Métodos e composições para integração genômica
|
US20220332780A1
(en)
|
2019-09-10 |
2022-10-20 |
Obsidian Therapeutics, Inc. |
Ca2-il15 fusion proteins for tunable regulation
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US20240139242A1
(en)
|
2019-10-18 |
2024-05-02 |
Trustees Of Boston University |
Cal-t constructs and uses thereof
|
US20220389381A1
(en)
|
2019-10-25 |
2022-12-08 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
MX2022006288A
(es)
*
|
2019-11-25 |
2022-06-08 |
Univ Kyoto |
Banco de celulas maestras de celulas t.
|
JP2023504081A
(ja)
*
|
2019-11-27 |
2023-02-01 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
神経膠芽細胞腫及び他の癌を処置するためのナチュラルキラー細胞免疫療法
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
CA3161104A1
(en)
|
2019-12-11 |
2021-06-17 |
Cecile Chartier-Courtaud |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
AU2020415318A1
(en)
|
2019-12-23 |
2022-07-14 |
Cellectis |
New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
CA3166420A1
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Il2 orthologs and methods of use
|
BR112022016657A2
(pt)
|
2020-02-24 |
2022-12-20 |
Allogene Therapeutics Inc |
Células car-t bcma com atividades melhoradas
|
JOP20220206A1
(ar)
|
2020-03-03 |
2023-01-30 |
Janssen Biotech Inc |
الخلايا التائية واستخداماتها
|
WO2021183675A2
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
WO2021183207A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技(香港)有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
US20230172987A1
(en)
|
2020-05-04 |
2023-06-08 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
AU2021268253A1
(en)
|
2020-05-06 |
2022-12-08 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
EP3910331A1
(en)
|
2020-05-15 |
2021-11-17 |
iOmx Therapeutics AG |
Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
|
WO2022003158A1
(en)
|
2020-07-03 |
2022-01-06 |
Cellectis S.A. |
Method for determining potency of chimeric antigen receptor expressing immune cells
|
WO2022008027A1
(en)
|
2020-07-06 |
2022-01-13 |
Iomx Therapeutics Ag |
Antibodies binding igv of igsf11 (vsig3) and uses thereof
|
WO2022016119A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
EP4185616A1
(en)
|
2020-07-24 |
2023-05-31 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
JP2023535501A
(ja)
|
2020-07-30 |
2023-08-17 |
アンスティテュ・クリー |
Socs1に欠陥のある免疫細胞
|
CA3186325A1
(en)
|
2020-07-31 |
2022-02-03 |
Andre Choulika |
Dual car-t cells
|
US20220031751A1
(en)
|
2020-08-03 |
2022-02-03 |
Kyverna Therapeutics, Inc. |
Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same
|
US20230321239A1
(en)
|
2020-08-14 |
2023-10-12 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Chimeric antigen receptor t cells for treating autoimmunity
|
EP4225330A1
(en)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
CA3197423A1
(en)
|
2020-11-04 |
2022-05-12 |
Daniel Getts |
Engineered chimeric fusion protein compositions and methods of use thereof
|
JP2023548432A
(ja)
|
2020-11-11 |
2023-11-16 |
ヨーロピアン モレキュラー バイオロジー ラボラトリー |
遺伝子療法のための改変ウイルス粒子
|
WO2022109277A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Pact Pharma, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFβRII ENGINEERED T CELL THERAPY
|
US20220162288A1
(en)
|
2020-11-25 |
2022-05-26 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
WO2022112596A1
(en)
|
2020-11-30 |
2022-06-02 |
Cellectis Sa |
Use of aminoquinoline compounds for higher gene integration
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
CA3202473A1
(en)
|
2020-12-17 |
2022-06-23 |
Friedrich Graf Finckenstein |
Treatment of cancers with tumor infiltrating lymphocytes
|
EP4263600A1
(en)
|
2020-12-18 |
2023-10-25 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
WO2022135457A1
(zh)
*
|
2020-12-23 |
2022-06-30 |
广东菲鹏制药股份有限公司 |
一种抗pd-l1抗体及其应用
|
CN117396607A
(zh)
|
2020-12-30 |
2024-01-12 |
阿劳诺斯治疗公司 |
包含多顺反子表达盒的重组载体及其使用方法
|
EP4284919A1
(en)
|
2021-01-29 |
2023-12-06 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
WO2022165419A1
(en)
|
2021-02-01 |
2022-08-04 |
Kyverna Therapeutics, Inc. |
Methods for increasing t-cell function
|
TW202304480A
(zh)
|
2021-03-19 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球(til)中之與cd39/cd69選擇及基因剔除相關之til擴增之方法
|
TW202305118A
(zh)
|
2021-03-23 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球之cish基因編輯及其在免疫療法中之用途
|
WO2022225981A2
(en)
|
2021-04-19 |
2022-10-27 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
EP4330288A1
(en)
|
2021-04-30 |
2024-03-06 |
Cellectis S.A. |
New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
|
CA3217914A1
(en)
|
2021-05-04 |
2022-11-10 |
Kevin BRAY |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
EP4340850A1
(en)
|
2021-05-17 |
2024-03-27 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
CA3218475A1
(en)
|
2021-05-21 |
2022-11-24 |
Shipra DAS |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
KR20240021826A
(ko)
|
2021-06-15 |
2024-02-19 |
알로젠 테라퓨틱스 인코포레이티드 |
동종이계 car t 세포 지속성을 연장시키기 위한 숙주 cd70+ 동종반응성 세포의 선택적 표적화
|
WO2023004074A2
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
TW202327631A
(zh)
|
2021-07-28 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者
|
AU2022318416A1
(en)
|
2021-07-29 |
2024-01-25 |
Takeda Pharmaceutical Company Limited |
Engineered immune cell that specifically targets mesothelin and uses thereof
|
WO2023014922A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
IL311333A
(en)
|
2021-09-09 |
2024-05-01 |
Iovance Biotherapeutics Inc |
Processes for the production of TIL products using a strong PD-1 TALEN
|
TW202331735A
(zh)
|
2021-10-27 |
2023-08-01 |
美商艾歐凡斯生物治療公司 |
協調用於患者特異性免疫療法之細胞之製造的系統及方法
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
AU2022395500A1
(en)
|
2021-11-23 |
2024-05-23 |
Cellectis Sa |
New tale protein scaffolds with improved on-target/off-target activity ratios
|
WO2023126458A1
(en)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
WO2023133509A2
(en)
*
|
2022-01-08 |
2023-07-13 |
Carogen Corporation |
Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
WO2023233003A1
(en)
|
2022-06-03 |
2023-12-07 |
Cellectis Sa |
Tale base editors for gene and cell therapy
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
WO2024022509A1
(en)
*
|
2022-07-29 |
2024-02-01 |
Nanjing Legend Biotech Co., Ltd. |
Methods for promoting persistence of cell therapy
|
WO2024055018A1
(en)
|
2022-09-09 |
2024-03-14 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
WO2024055017A1
(en)
|
2022-09-09 |
2024-03-14 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024094775A1
(en)
|
2022-11-03 |
2024-05-10 |
Cellectis S.A. |
Enhancing efficacy and safety of t-cell-mediated immunotherapy
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
CN116987699A
(zh)
*
|
2023-09-05 |
2023-11-03 |
深圳市艾迪贝克生物医药有限公司 |
用于制备通用型car-t细胞的基因片段、其工具***及应用
|
CN117164714B
(zh)
*
|
2023-10-08 |
2024-04-23 |
北京奇迈永华生物科技有限公司 |
一种靶向bcma的抗体及其应用
|